JP2550909B2 - Oral composition - Google Patents
Oral compositionInfo
- Publication number
- JP2550909B2 JP2550909B2 JP6075317A JP7531794A JP2550909B2 JP 2550909 B2 JP2550909 B2 JP 2550909B2 JP 6075317 A JP6075317 A JP 6075317A JP 7531794 A JP7531794 A JP 7531794A JP 2550909 B2 JP2550909 B2 JP 2550909B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- aluminum
- carboxylic acid
- composition according
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 41
- -1 phosphoric acid compound Chemical class 0.000 claims description 60
- 229910052782 aluminium Inorganic materials 0.000 claims description 39
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 36
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 33
- 210000005239 tubule Anatomy 0.000 claims description 30
- 210000004268 dentin Anatomy 0.000 claims description 24
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 19
- 208000037804 stenosis Diseases 0.000 claims description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 17
- 235000006408 oxalic acid Nutrition 0.000 claims description 15
- 235000011007 phosphoric acid Nutrition 0.000 claims description 12
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 230000009610 hypersensitivity Effects 0.000 claims description 7
- 150000003863 ammonium salts Chemical class 0.000 claims description 6
- 159000000000 sodium salts Chemical class 0.000 claims description 6
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 5
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims description 5
- 235000002949 phytic acid Nutrition 0.000 claims description 5
- 239000000467 phytic acid Substances 0.000 claims description 5
- 229940068041 phytic acid Drugs 0.000 claims description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 5
- 229940005657 pyrophosphoric acid Drugs 0.000 claims description 5
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 5
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 5
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 230000036262 stenosis Effects 0.000 description 15
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229940034610 toothpaste Drugs 0.000 description 11
- 239000000606 toothpaste Substances 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 210000003298 dental enamel Anatomy 0.000 description 5
- 201000002170 dentin sensitivity Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000035154 Hyperesthesia Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 229940051866 mouthwash Drugs 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 description 3
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 2
- KLZUFWVZNOTSEM-UHFFFAOYSA-K Aluminium flouride Chemical compound F[Al](F)F KLZUFWVZNOTSEM-UHFFFAOYSA-K 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000002697 Tooth Abrasion Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- JLPAMKUIIFHLBH-UHFFFAOYSA-N 1,2-dihydroxypropane-1-sulfonic acid Chemical compound CC(O)C(O)S(O)(=O)=O JLPAMKUIIFHLBH-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical class CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 1
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical class CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 1
- FUWHCTSQIAULAK-UHFFFAOYSA-N 4-(2-hydroxyethyl)benzoic acid Chemical compound OCCC1=CC=C(C(O)=O)C=C1 FUWHCTSQIAULAK-UHFFFAOYSA-N 0.000 description 1
- SQVHRJXGOIGDTD-UHFFFAOYSA-N 4-(3-hydroxypropyl)benzoic acid Chemical compound OCCCC1=CC=C(C(O)=O)C=C1 SQVHRJXGOIGDTD-UHFFFAOYSA-N 0.000 description 1
- KGKRDKISRBUFHF-UHFFFAOYSA-N 4-(4-hydroxybutyl)benzoic acid Chemical compound OCCCCC1=CC=C(C(O)=O)C=C1 KGKRDKISRBUFHF-UHFFFAOYSA-N 0.000 description 1
- WWYFPDXEIFBNKE-UHFFFAOYSA-N 4-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=C(C(O)=O)C=C1 WWYFPDXEIFBNKE-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical group CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 229910004074 SiF6 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CGJYBOQUNXQLDA-UHFFFAOYSA-L aluminum;2-hydroxybutanedioate Chemical compound [Al+3].[O-]C(=O)C(O)CC([O-])=O CGJYBOQUNXQLDA-UHFFFAOYSA-L 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YGIMPIJCOSFCOM-UHFFFAOYSA-H dialuminum;2,3-dihydroxybutanedioate Chemical compound [Al+3].[Al+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O YGIMPIJCOSFCOM-UHFFFAOYSA-H 0.000 description 1
- GSDVGWFPDRNJGY-UHFFFAOYSA-H dialuminum;propanedioate Chemical compound [Al+3].[Al+3].[O-]C(=O)CC([O-])=O.[O-]C(=O)CC([O-])=O.[O-]C(=O)CC([O-])=O GSDVGWFPDRNJGY-UHFFFAOYSA-H 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- FXNRKXSSLJKNGH-UHFFFAOYSA-L dipotassium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [K+].[K+].[O-]P([O-])(F)=O FXNRKXSSLJKNGH-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical class O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- KFHHGNBIPJDZPH-UHFFFAOYSA-D pentamagnesium [oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O KFHHGNBIPJDZPH-UHFFFAOYSA-D 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 239000010672 sassafras oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は象牙質知覚過敏症を有効
に予防し、治療することができる口腔用組成物に関す
る。TECHNICAL FIELD The present invention relates to an oral composition capable of effectively preventing and treating dentin hyperesthesia.
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】象牙質
知覚過敏症とは臨床症状に因んだ疾患名であって、歯の
う蝕、咬耗、磨耗などの原因により、或いは歯肉の退縮
などの原因により、歯のエナメル質又はセメント質が消
失して象牙質が露出し、この象牙質に温熱的、化学的、
機械的、物理化学的、電気的などの種々の外来的な刺激
が与えられることによって非常に不快な痛みを一過性に
生ずるものであり(誘発痛)、例えば砂糖を多く含む食
品や酸味の強い果物等を摂取した時、冷たい水を飲んだ
時、歯を磨く時などに経験する一過性の痛みであるが、
これらの痛みは日常の食生活、口腔衛生の保持に少なか
らず悪影響を与えるものである。BACKGROUND OF THE INVENTION Dentin hypersensitivity is a name of a disease caused by clinical symptoms, which is caused by dental caries, abrasion, abrasion, or gingival recession. Due to such causes, the enamel or cement of the tooth disappears and the dentin is exposed, and the dentin is heated thermally, chemically,
It causes a very unpleasant pain transiently (excited pain) due to various external stimuli such as mechanical, physicochemical and electrical (e.g., induced pain). It is a temporary pain that is experienced when ingesting strong fruits, drinking cold water, brushing teeth, etc.
These pains adversely affect daily diet and oral hygiene.
【0003】この象牙質における痛みの発現機構として
は、上記の電気的刺激や化学的刺激などの誘発因子が
(1)直接象牙質内にある象牙細管を経て、歯髄の神経
を刺激するという考え方と(2)象牙質に存在する象牙
細管において、これら誘発因子の刺激が象牙細管内に存
する象牙細管液を移動させ、神経を刺激するという考え
方があり、現在では、(2)の考え方をエム・ブレンス
トレーム(M.Branstrom)〔カロリンスカ・
インスティテュート〕、堀内博〔東北大歯学部〕、パッ
シュレー(Pashley)〔ジョージア薬大〕、ビー
・マシュー(B.Matthew)〔ブリストル大学〕
らの学者が支持し、(2)の考え方が主流を占めてい
る。即ち、ヒト臼歯における象牙細管はエナメル側には
直径が約1.0μm程度のものが2〜3万個、または歯
髄側には直径が約3.0μm程度のものが3〜4万個分
布しているが、エナメル質又はセメント質が消失した場
合、外来の刺激が露出象牙質の表面に加わることによっ
て象牙細管内の体液の移動を引き起こし、この体液の移
動によって歯髄の知覚神経を興奮させ、痛みとして感じ
るというものである。The mechanism of pain development in dentin is that the above-mentioned induction factors such as electrical stimulation and chemical stimulation (1) directly stimulate nerves in the pulp through dentinal tubules in dentin. (2) In the dentinal tubules present in dentin, there is an idea that stimulation of these inducing factors moves the dentinal tubule fluid existing in the dentinal tubules to stimulate nerves. Currently, the idea of (2) is used.・ M.Branstrom [Karolinska ・
Institute], Hiroshi Horiuchi [Faculty of Dentistry, Tohoku University], Pashley [Georgia Pharmaceutical], B. Matthew [University of Bristol]
Supported by these scholars, the idea of (2) is the mainstream. That is, the number of dentinal tubules in human molars is about 20,000 on the enamel side and about 30,000 on the enamel side, and about 30,000 to 40,000 on the dental pulp side is about 3.0 μm in diameter. However, when the enamel or cementum disappears, external stimuli cause the movement of fluid in the dentinal tubule by adding to the surface of the exposed dentin, and the movement of this fluid excites the sensory nerves of the pulp, It is felt as pain.
【0004】従って、知覚過敏症の痛みを緩和、除去
し、或いは予防するには、この象牙細管の入口を封鎖、
狭窄することによって刺激の伝達を抑制、阻止すること
が有効である。Therefore, in order to alleviate, eliminate or prevent the pain of hyperesthesia, the entrance of this dentinal tubule is blocked,
It is effective to suppress and block the transmission of stimulation by narrowing.
【0005】従来、この象牙質知覚過敏症の臨床的な治
療法としては、(a)欠損したエナメルの修復を兼ねて
行う充填法、(b)腐蝕剤、硬化促進剤、抗炎症剤、第
2象牙質形成促進剤等の貼薬を用いる方法、(c)8%
ZnCl2又は1〜2%NaFの水溶液を使用するイオ
ン導入法、(d)覆髄又は裏装による方法、(e)抜髄
又は根管治療法などが採用されている。Conventionally, as clinical treatments for this hypersensitivity of dentin, (a) a filling method which also serves to repair a defective enamel, (b) a corrosive agent, a hardening accelerator, an anti-inflammatory agent, 2 Method using patch such as dentin formation promoter, (c) 8%
An iontophoresis method using an aqueous solution of ZnCl 2 or 1 to 2% NaF, (d) a method of covering or lining the pulp, (e) a method of demyelination or a root canal treatment, and the like are adopted.
【0006】また、象牙質知覚過敏症の予防或いは治療
を目的とした口腔用組成物もいくつか提案されている
が、従来のこの種の口腔用組成物はその殆どが象牙細管
の狭窄又は閉塞を企図したものではなく、即ち象牙細管
内において、細管液を移動させて神経を刺激することを
妨げるのではなく、主として神経の鈍麻作用を利用した
間接的な予防、治療技術であった。[0006] Although some oral compositions for the purpose of preventing or treating dentin hypersensitivity have been proposed, most of the conventional oral compositions of this type are narrowed or occluded in dentinal tubules. That is, it was an indirect preventive and therapeutic technique that mainly utilizes the blunt action of nerves, rather than hindering the movement of the tubule fluid to stimulate the nerves in the dentinal tubules.
【0007】[0007]
【課題を解決するための手段及び作用】本発明者らは上
記事情に鑑み、神経の鈍麻作用を利用した間接的な技術
に依らず、象牙質内の象牙細管を狭窄又は閉塞すること
により象牙質知覚過敏症を予防、治療することができる
口腔用組成物につき鋭意研究を進めた結果、口腔用組成
物中にアルミニウムとカルボン酸根とが溶解状態で存在
し、かつそのアルミニウム根1モルに対するカルボン酸
根のモル比が6以下である象牙細管狭窄閉塞有効成分に
正リン酸、グリセロリン酸、ピロリン酸、トリポリリン
酸、ヘキサメタリン酸、フィチン酸、エタン−1−ヒド
ロキシ−1,1−ジホスホン酸及びこれらのナトリウム
塩、カリウム塩、アンモニウム塩から選ばれる水溶性リ
ン酸化合物を併用するか、又はアルミニウムとシュウ酸
以外のカルボン酸根とが溶解状態で含有され、かつその
アルミニウム根1モルに対するカルボン酸根のモル比が
6以下である象牙細管狭窄閉塞有効成分にシュウ酸化合
物を併用し、かつ組成物のpHを5以上とした場合、象
牙細管を狭窄又は閉塞する効果が高く、象牙質知覚過敏
症を有効に予防、治療し得ることを知見した。SUMMARY OF THE INVENTION In view of the above circumstances, the inventors of the present invention have conceived dentin by constricting or occluding dentinal tubules in dentin without relying on an indirect technique utilizing the blunt action of nerves. As a result of intensive research on an oral composition capable of preventing and treating hypersensitivity, aluminum and carboxylic acid radicals are present in a dissolved state in the oral composition, and 1 mol of the aluminum root Orthophosphoric acid, glycerophosphoric acid, pyrophosphoric acid, tripolyphosphoric acid, hexametaphosphoric acid, phytic acid, ethane-1-hydroxy-1,1-diphosphonic acid, and these as the active ingredient of dentinal tubule stenosis occlusion with a molar ratio of acid roots of 6 or less Water-soluble phosphoric acid compound selected from sodium salt, potassium salt and ammonium salt is used in combination, or carboxylic acid other than aluminum and oxalic acid When and are contained in a dissolved state, and the molar ratio of carboxylic acid roots to 1 mole of aluminum roots is 6 or less, an oxalic acid compound is used in combination with the dentinal tubule stenosis-occluding active ingredient, and the pH of the composition is 5 or more. It was found that the effect of stenosis or occlusion of dentin tubules is high, and dentin hypersensitivity can be effectively prevented or treated.
【0008】即ち、従来より知覚過敏症に対する処置薬
剤としてアルミニウムクロロヒドロアラントイネイトを
使用することが知られている(米国特許第351451
3号)が、後述する実験例に示したように、本発明者ら
が象牙細管狭窄閉塞効果を調べるために採用したパッシ
ュレー(Pashley)らによる評価法(象牙細管の
物質通過性の評価)による場合、その有効性は小さいも
のである。That is, it has been conventionally known to use aluminum chlorohydroallantoinate as a drug for treating hypersensitivity (US Pat. No. 3,541,451).
No. 3) is based on an evaluation method (evaluation of substance permeability of dentinal tubules) by Pashley et al., Which was adopted by the present inventors for investigating occlusive stenosis occlusion effect, as shown in Experimental Examples described later. If so, its effectiveness is small.
【0009】また従来、歯石予防を目的としてアルミニ
ウム化合物をフッ化物と組み合せた口腔用組成物が知ら
れており(米国特許第4146605号)、この組成物
中にはクエン酸や乳酸を配合し得ることも開示されてい
るが、この組成物のpHは4.5以下であり、本発明者
らの検討によると、後述する実験例から明らかなよう
に、このような低pHでは象牙細管狭窄閉塞効果はな
い。更に、米国特許第3651207号には、アルミニ
ウムジハイドロキシアラントイネート、クエン酸、酒石
酸を含み、更にリン酸一水素ナトリウムを配合した洗口
剤が開示されているが、この洗口剤はアルミニウム含量
がクエン酸、酒石酸に対し少な過ぎ、同様に知覚過敏症
鈍麻効果はないものである。Further, a composition for oral cavity in which an aluminum compound is combined with a fluoride for the purpose of preventing tartar has been known (US Pat. No. 4,146,605), and citric acid or lactic acid may be added to the composition. However, the pH of this composition is 4.5 or less, and according to the study by the present inventors, as is clear from the experimental examples described later, at such low pH, dentinal tubule stenosis is occluded. It has no effect. Further, U.S. Pat. No. 3,651,207 discloses a mouthwash containing aluminum dihydroxyallantoinate, citric acid and tartaric acid, and further containing sodium monohydrogen phosphate. However, it is too little for citric acid and tartaric acid, and similarly, it has no hyperalgesic and blunting effect.
【0010】ところが、本発明者らの検討の結果では、
アルミニウムとカルボン酸根、特にヒドロキシカルボン
酸根とを特定モル比、即ち前者1モルに対し後者6モル
以下、好適には0.3/n〜6/nモル(nは一分子中
のカルボン酸根の数を示す)範囲で系中に溶解存在さ
せ、かつ系のpHを5以上、好適には5〜10とし、更
にこれに正リン酸、グリセロリン酸、ピロリン酸、トリ
ポリリン酸、ヘキサメタリン酸、フィチン酸、エタン−
1−ヒドロキシ−1,1−ジホスホン酸及びこれらのナ
トリウム塩、カリウム塩、アンモニウム塩から選ばれる
水溶性リン酸化合物を配合した場合、或いは上記カルボ
ン酸根としてシュウ酸以外のカルボン酸根を使用し、こ
れにシュウ酸化合物を配合した場合、意外にも優れた象
牙細管狭窄閉塞効果を発揮し、象牙質知覚過敏症の予
防、治療に極めて有効であることを知見し、本発明をな
すに至ったものである。However, according to the results of the study by the present inventors,
Aluminum and a carboxylic acid radical, in particular a hydroxycarboxylic acid radical, in a specific molar ratio, that is, the latter 6 mol or less relative to the former 1 mol, preferably 0.3 / n to 6 / n mol (n is the number of carboxylic acid radicals in one molecule) The pH of the system is 5 or more, preferably 5 to 10, and further phosphoric acid, glycerophosphoric acid, pyrophosphoric acid, tripolyphosphoric acid, hexametaphosphoric acid, phytic acid, Ethane
When 1-hydroxy-1,1-diphosphonic acid and a sodium salt thereof, potassium salt, or a water-soluble phosphate compound selected from ammonium salt is blended, or a carboxylic acid radical other than oxalic acid is used as the carboxylic acid radical, When an oxalic acid compound was added to the composition, it surprisingly exhibited an excellent dentinal tubule stenosis occlusion effect, and was found to be extremely effective in the prevention and treatment of dentin hypersensitivity, which led to the present invention. Is.
【0011】従って、本発明はアルミニウムとカルボン
酸根とを溶解状態で含有し、かつそのアルミニウム1モ
ルに対するカルボン酸根のモル比が6以下である象牙細
管狭窄閉塞有効成分を配合していると共に、正リン酸、
グリセロリン酸、ピロリン酸、トリポリリン酸、ヘキサ
メタリン酸、フィチン酸、エタン−1−ヒドロキシ−
1,1−ジホスホン酸及びこれらのナトリウム塩、カリ
ウム塩、アンモニウム塩から選ばれる水溶性リン酸化合
物を配合してなり、かつpHが5以上であることを特徴
とする口腔用組成物及びアルミニウムとシュウ酸以外の
カルボン酸根とを溶解状態で含有し、かつそのアルミニ
ウム1モルに対するカルボン酸根のモル比が6以下であ
る象牙細管狭窄閉塞有効成分を配合していると共に、シ
ュウ酸化合物を配合してなり、かつpHが5以上である
ことを特徴とする象牙質知覚過敏症用口腔用組成物を提
供する。Accordingly, the present invention contains an active ingredient of dentinal tubule stenosis obstruction which contains aluminum and carboxylic acid radicals in a dissolved state and has a molar ratio of carboxylic acid radicals to 1 mol of aluminum of 6 or less. phosphoric acid,
Glycerophosphoric acid, pyrophosphoric acid, tripolyphosphoric acid, hexametaphosphoric acid, phytic acid, ethane-1-hydroxy-
1,1-diphosphonic acid and a water-soluble phosphoric acid compound selected from these sodium salts, potassium salts and ammonium salts, and having a pH of 5 or more, and an oral composition and aluminum A dentin stenosis stenosis-occluding active ingredient containing a carboxylic acid root other than oxalic acid in a dissolved state and having a molar ratio of the carboxylic acid root to 1 mole of aluminum of 6 or less is added, and an oxalic acid compound is added. And a pH of 5 or more, an oral composition for hypersensitivity of dentin.
【0012】本発明に係る口腔用組成物は、練歯磨、潤
製歯磨等の歯磨類、液状又はゲル状の塗布剤、洗口剤、
デンタルフロス、オーラルバンドなどとして用いられる
ものであって、象牙細管狭窄閉塞有効成分としてアルミ
ニウムとカルボン酸根とを溶解状態においてアルミニウ
ム根1モルに対しカルボン酸根を6モル以下の割合で含
有させたものである。なお、溶解状態とは、上記の成分
が口腔用組成物中に全部可溶化されている場合のみに限
られず、一部沈澱状態にある場合も包含する。また、上
記成分はそれぞれ単独にイオンとして可溶化していても
キレートされた形て可溶化されていてもよい。The oral composition according to the present invention is a toothpaste such as a toothpaste or a moisturized toothpaste, a liquid or gel coating agent, a mouthwash,
It is used as a dental floss, an oral band, etc., and contains carboxylic acid radicals in an amount of 6 mol or less per 1 mol of aluminum radicals in a dissolved state of aluminum and carboxylic acid radicals as active ingredients for dentinal stenosis stenosis. is there. The dissolved state is not limited to the case where all of the above components are solubilized in the oral composition, and also includes the case where the components are partially precipitated. Further, each of the above components may be solubilized as an ion alone or may be solubilized in a chelated form.
【0013】ここで、アルミニウム、カルボン酸根は、
カルボン酸アルミニウムとして与えてもよく、或いはカ
ルボン酸基を含まないアルミニウム化合物とカルボン酸
又はそのアルミニウム塩以外の塩をそれぞれ別個に配合
することにより与えてもよい。この場合、カルボン酸ア
ルミニウムとしては、乳酸アルミニウム、グルコン酸ア
ルミニウム、グリコール酸アルミニウム等のモノカルボ
ン酸アルミニウム、マロン酸アルミニウム、グルタル酸
アルミニウム、リンゴ酸アルミニウム、酒石酸アルミニ
ウム等のジカルボン酸アルミニウム、クエン酸アルミニ
ウム等のトリカルボン酸アルミニウムなどの正塩及び塩
基性アルミニウムなどの変則塩(abnormal s
alt)などが挙げられる。また、これらのカルボン酸
アルミニウム以外のアルミニウム化合物としては、Al
(NH4)(SO4)2,AlCl3,AlF3,〔Al
(OH)2Cl〕x,Al(NO3)3,KAl(S
O 4)2,NaAl(SO4)2,Al2(SO4)3,Al
(SiF6)3などの可溶性アルミニウム化合物が使用で
き、更にカルボン酸及びその塩としては上述したモノ、
ジ、トリカルボン酸及びそのアルカリ金属塩などが使用
できる。なお、本発明においてはこれらの化合物の2種
以上を併用し得る。Here, aluminum and carboxylic acid radicals are
It may be given as aluminum carboxylate, or
Aluminum compounds and carboxylic acids that do not contain rubonic acid groups
Or, the salts other than the aluminum salt are blended separately.
May be given by doing. In this case, the carboxylic acid
Luminium includes aluminum lactate and gluconate
Monocarbo such as aluminum and aluminum glycolate
Aluminum acid salt, aluminum malonate, glutaric acid
Aluminum, aluminum malate, aluminum tartrate
Aluminum dicarboxylates such as um and aluminum citrate
Normal salts and salts of aluminum tricarboxylates such as um
Anomalous salts such as basic aluminum (abnormals)
Alt) and the like. Also, these carboxylic acids
Aluminum compounds other than aluminum include Al
(NHFour) (SOFour)2, AlCl3, AlF3, [Al
(OH)2Cl]x, Al (NO3)3, KAl (S
O Four)2, NaAl (SOFour)2, Al2(SOFour)3, Al
(SiF6)3Soluble aluminum compounds such as
Further, as the carboxylic acid and its salt, the above-mentioned mono,
Di, tricarboxylic acid and its alkali metal salts are used
it can. In the present invention, two kinds of these compounds are used.
The above may be used in combination.
【0014】上述したカルボン酸根を有する化合物のう
ちでは、特にヒドロキシカルボン酸根を有する化合物が
好ましく、なかでも乳酸、グリコール酸、グルコン酸等
のヒドロキシモノカルボン酸化合物が好ましい。Among the compounds having a carboxylic acid group described above, a compound having a hydroxycarboxylic acid group is particularly preferable, and a hydroxymonocarboxylic acid compound such as lactic acid, glycolic acid or gluconic acid is particularly preferable.
【0015】本発明においては、上述したアルミニウム
及びカルボン酸根はアルミニウム1モルに対しカルボン
酸根6モル以下の割合で溶解状態において配合するもの
であるが、この場合特にアルミニウム1モルに対しカル
ボン酸根を6/n以下(但し、nは一分子中のカルボン
酸根の数を示す。即ち、モノカルボン酸の場合はn=
1、ジカルボン酸の場合はn=2、トリカルボン酸の場
合はn=3である)、より望ましくは0.3/n〜6/
nのモル数とすることが好ましい。更に好ましくは、モ
ノカルボン酸の場合0.7〜5、特に1〜4、ジカルボ
ン酸の場合0.2〜2.5、特に0.3〜2、トリカル
ボン酸の場合0.1〜2、特に0.2〜1.5モルであ
る。In the present invention, the above-mentioned aluminum and carboxylic acid radicals are mixed in a dissolved state at a ratio of 6 mol or less of carboxylic acid radicals to 1 mol of aluminum. In this case, particularly 6 carboxylic acid radicals to 1 mol of aluminum are mixed. / N or less (where n is the number of carboxylic acid radicals in one molecule. That is, in the case of monocarboxylic acid, n =
1, n = 2 in the case of dicarboxylic acid, n = 3 in the case of tricarboxylic acid), and more preferably 0.3 / n to 6 /
It is preferable that the number of moles is n. More preferably, it is 0.7 to 5, especially 1 to 4 in the case of monocarboxylic acid, 0.2 to 2.5 in the case of dicarboxylic acid, especially 0.3 to 2, and 0.1 to 2 in the case of tricarboxylic acid, and particularly It is 0.2 to 1.5 mol.
【0016】なお、アルミニウムの含有量は必ずしも制
限されないが、可溶化されたものが組成物全体の0.0
1〜10%(重量%、以下同じ)、特に0.1〜5%で
あることが好ましい。The content of aluminum is not necessarily limited, but solubilized aluminum is 0.0% of the total composition.
It is preferably 1 to 10% (weight%, the same applies hereinafter), and particularly preferably 0.1 to 5%.
【0017】本発明においては、アルミニウム及びカル
ボン酸根に加え、更に特定の水溶性リン酸化合物を配合
するもので、これにより象牙質知覚過敏症の予防、治療
効果を更に改善することができる。In the present invention, in addition to aluminum and carboxylic acid radical, a specific water-soluble phosphoric acid compound is further added, whereby the preventive and therapeutic effects of dentin hypersensitivity can be further improved.
【0018】ここで、リン酸化合物としては、水溶性で
ある正リン酸、グリセロリン酸、ピロリン酸、トリポリ
リン酸、ヘキサメタリン酸、フィチン酸、エタン−1−
ヒドロキシ−1,1−ジホスホン酸及びこれらのナトリ
ウム塩、カリウム塩、アンモニウム塩から選ばれる1種
又は2種以上が使用される。なお、これらリン酸化合物
も溶解状態で口腔用組成物に含有させるものであり、そ
の含有量は可溶化されたものが組成物全体の0.01〜
10%、特に0.1〜5%とすることが好ましい。As the phosphoric acid compound, water-soluble orthophosphoric acid, glycerophosphoric acid, pyrophosphoric acid, tripolyphosphoric acid, hexametaphosphoric acid, phytic acid, ethane-1-
Hydroxy-1,1-diphosphonic acid and one or more selected from sodium salt, potassium salt and ammonium salt thereof are used. In addition, these phosphate compounds are also contained in the oral composition in a dissolved state, and the content of the solubilized compound is 0.01 to 0.01% of the entire composition.
It is preferably set to 10%, particularly 0.1 to 5%.
【0019】また、本発明は上述したようにカルボン酸
化合物を配合するものであり、カルボン酸化合物として
はヒドロキシカルボン酸化合物が好ましいものである
が、この場合カルボン酸化合物として、シュウ酸化合物
以外のカルボン酸化合物を用いると共に、これにシュウ
酸化合物とを併用することによっても上記特定の水溶性
リン酸化合物を配合した場合と同様の効果が得られ、従
ってシュウ酸化合物とシュウ酸化合物以外のカルボン酸
化合物、特にヒドロキシカルボン酸化合物とを併用する
ことも有効である。In the present invention, a carboxylic acid compound is blended as described above, and a hydroxycarboxylic acid compound is preferable as the carboxylic acid compound. In this case, the carboxylic acid compound other than the oxalic acid compound is used. By using a carboxylic acid compound together with an oxalic acid compound, the same effect as in the case of blending the above specific water-soluble phosphoric acid compound can be obtained. Therefore, an oxalic acid compound and a carboxylic acid other than the oxalic acid compound can be obtained. It is also effective to use an acid compound, especially a hydroxycarboxylic acid compound in combination.
【0020】この場合、シュウ酸化合物としては、シュ
ウ酸及びそのナトリウム塩、カリウム塩、アンモニウム
塩などが挙げられ、これらの1種又は2種以上が使用し
得、その口腔用組成物中における含有量は可溶化された
ものがシュウ酸根として0.07〜5%、特に0.1〜
3%であることが好ましい。In this case, examples of the oxalic acid compound include oxalic acid and its sodium salt, potassium salt, ammonium salt and the like, and one or more of these may be used, and their content in the oral composition. The amount of solubilized oxalate is 0.07-5%, especially 0.1-0.1%.
It is preferably 3%.
【0021】本発明の口腔用組成物のその他の成分とし
ては、その種類、使用目的等に応じた適宜な成分が用い
られる。As the other components of the composition for oral cavity of the present invention, appropriate components are used depending on the type, purpose of use and the like.
【0022】例えば、歯磨類の場合には、第2リン酸カ
ルシウム・2水和物及び無水物、第1リン酸カルシウ
ム、第3リン酸カルシウム、炭酸カルシウム、ピロリン
酸カルシウム、酸化チタン、アルミナ、水和アルミナ、
沈降性シリカ、その他のシリカ系研磨剤、ケイ酸アルミ
ニウム、不溶性メタリン酸ナトリウム、不溶性メタリン
酸カリウム、第3リン酸マグネシウム、炭酸マグネシウ
ム、硫酸カルシウム、ベントナイト、ケイ酸ジルコニウ
ム、合成樹脂等の1種又は2種以上を配合し得る(配合
量通常7〜99%、練歯磨の場合には10〜50%であ
るが、RDA値が10〜100程度、特に30〜60程
度になるように研磨剤、その配合量を選定することが好
ましい)。For example, in the case of toothpaste, dibasic calcium phosphate dihydrate and anhydride, monobasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, calcium pyrophosphate, titanium oxide, alumina, hydrated alumina,
Precipitable silica, other silica-based abrasives, aluminum silicate, insoluble sodium metaphosphate, insoluble potassium metaphosphate, magnesium triphosphate, magnesium carbonate, calcium sulfate, bentonite, zirconium silicate, synthetic resin, etc. or Two or more kinds may be blended (the blending amount is usually 7 to 99%, and in the case of toothpaste, it is 10 to 50%, but an RDA value of about 10 to 100, particularly about 30 to 60, an abrasive, It is preferable to select the blending amount).
【0023】また、練歯磨等のペースト形態の口腔用組
成物の場合には、粘結剤としてカラゲナン、カルボキシ
メチルセルロースナトリウム、メチルセルロース、ヒド
ロキシエチルセルロース、カルボキシメチルヒドロキシ
エチルセルロースナトリウムなどのセルロース誘導体、
アルギン酸ナトリウムなどのアルカリ金属アルギネー
ト、アルギン酸プロピレングリコールエステル、キサン
タンガム、トラガカントガム、カラヤガム、アラビアガ
ムなどのガム類、ポリビニルアルコール、ポリアクリル
酸ナトリウム、カルボキシビニルポリマー、ポリビニル
ピロリドンなどの合成粘結剤、ゲル化性シリカ、ゲル化
性アルミニウムシリカ、ビーガム、ラポナイトなどの無
機粘結剤等の1種又は2種以上が配合され得る(配合量
歯磨の場合通常0.5〜5%)。In the case of a paste-form oral composition such as toothpaste, a cellulose derivative such as carrageenan, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxymethyl hydroxyethyl cellulose sodium, etc. as a binder.
Alkali metal alginates such as sodium alginate, propylene glycol alginate, xanthan gum, tragacanth gum, gums such as karaya gum and gum arabic, polyvinyl alcohol, sodium polyacrylate, carboxyvinyl polymer, polyvinyl pyrrolidone and other synthetic binders, gelling property One or two or more kinds of inorganic binders such as silica, gelling aluminum silica, bee gum, and laponite may be blended (the blending amount is usually 0.5 to 5%).
【0024】更に、歯磨類、その他の液状、ペースト状
口腔用組成物の製造において、粘稠剤としてソルビッ
ト、グリセリン、エチレングリコール、プロピレングリ
コール、1,3−ブチレングリコール、ポリエチレング
リコール、ポリプロピレングリコール、キシリット、マ
ルチット、ラクチット等の1種又は2種以上を配合し得
る(配合量歯磨の場合通常10〜70%)。Further, in the production of toothpaste and other liquid or paste oral compositions, as a viscous agent, sorbit, glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, polyethylene glycol, polypropylene glycol, xylit. , Maltite, lactit and the like may be blended alone or in combination (the blending amount is usually 10 to 70% in the case of toothpaste).
【0025】また、ラウリル硫酸ナトリウム、ミリスチ
ル硫酸ナトリウム等のアルキル基の炭素数が8〜18で
ある高級アルキル硫酸エステルの水溶性塩、水素化ヤシ
油脂肪酸モノグリセリドモノ硫酸ナトリウム等の水溶性
の高級脂肪酸モノグリセリドモノ硫酸塩、ドデシルベン
ゼンスルホン酸ナトリウム等のアルキルアリールスルホ
ン酸塩、高級アルキルスルホン酸塩、1,2−ジヒドロ
キシプロパンスルホン酸塩の高級脂肪酸エステル、N−
ラウロイル、N−ミリストイル又はN−パルミトイルザ
ルコシンのナトリウム、カリウム又はエタノールアミン
塩等の低級脂肪族アミノカルボン酸化合物の実質的に飽
和の高級脂肪族アシルアミドなどのアニオン活性剤、ラ
ウロイルジエタノールアミド等のアルキロイルエタノー
ルアミド、ショ糖モノ及びジラウレート等の脂肪酸基の
炭素数が12〜18であるショ糖脂肪酸エステル、ラク
トース脂肪酸エステル、ラクチトール脂肪酸エステル、
マルチトール脂肪酸エステル、ステアリン酸モノグリセ
ライド、ポリオキシエチレンソルビタンモノラウレー
ト、ポリオキシエチレンソルビタンモノステアレート、
ポリオキシエチレン(10,20,40,60,80,
100モル)硬化ヒマシ油、エチレンオキサイドとプロ
ピレンオキサイドの重合物及びポリオキシエチレンポリ
オキシプロピレンモノラウリルエステル等のポリエチレ
ンオキサイドと脂肪酸、脂肪アルコール、多価アルコー
ル及びポリプロピレンオキサイドとの縮合生成物などの
ノニオン活性剤、ベタイン系、アミノ酸系などの両性活
性剤といった1種又は2種以上の界面活性剤(配合量通
常0〜7%、好ましくは0.2〜5%)を配合し得る。Further, water-soluble salts of higher alkyl sulfates having an alkyl group having 8 to 18 carbon atoms such as sodium lauryl sulfate and sodium myristyl sulfate, and water-soluble higher fatty acids such as hydrogenated coconut oil fatty acid monoglyceride sodium monosulfate. Monoglyceride monosulfate, alkylaryl sulfonate such as sodium dodecylbenzene sulfonate, higher alkyl sulfonate, higher fatty acid ester of 1,2-dihydroxypropane sulfonate, N-
Anionic activators such as substantially saturated higher aliphatic acylamides of lower aliphatic aminocarboxylic acid compounds such as sodium, potassium or ethanolamine salts of lauroyl, N-myristoyl or N-palmitoyl sarcosine, and alkyl groups such as lauroyl diethanolamide. Sucrose fatty acid ester, lactose fatty acid ester, lactitol fatty acid ester having 12 to 18 carbon atoms in fatty acid groups such as loylethanolamide, sucrose mono and dilaurate,
Maltitol fatty acid ester, stearic acid monoglyceride, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate,
Polyoxyethylene (10, 20, 40, 60, 80,
(100 mol) hydrogenated castor oil, a polymer of ethylene oxide and propylene oxide, and nonionic activity such as a condensation product of polyethylene oxide such as polyoxyethylene polyoxypropylene monolauryl ester with a fatty acid, a fatty alcohol, a polyhydric alcohol and polypropylene oxide. One or two or more kinds of surfactants (compounding amount usually 0 to 7%, preferably 0.2 to 5%) such as agents, betaine-based and amino acid-based amphoteric surfactants may be added.
【0026】本発明の口腔用組成物には、更にサッカリ
ンナトリウム、ステビオサイド、ネオヘスペリジルジヒ
ドロカルコン、グリチルリチン、ペリラルチン、タウマ
チン、アスパラチルフェニルアラニンメチルエステル、
p−メトキシシンナミックアルデヒド、ショ糖、乳糖、
果糖、サイクラミン酸ナトリウムなどの甘味剤(0〜1
%、好ましくは0.01〜0.5%)、p−ヒドロキシ
メチルベンゾイックアシド、p−ヒドロキシエチルベン
ゾイックアシド、p−ヒドロキシプロピルベンゾイック
アシド、p−ヒドロキシブチルベンゾイックアシド、安
息香酸ナトリウム、低級脂肪酸モノグリセライドなどの
防腐剤、ウインターグリーン油、スペアミント油、ペパ
ーミント油、サッサフラス油、丁字油、ユーカリ油など
の香料、ゼラチン、ペプトン、アルギニン塩酸塩、アル
ブミン、カゼイン、増白剤、シリコーン、色素、その他
の成分を配合し得、例えば練歯磨の場合には上記した所
望の成分を適量の水と練合することにより製造し得る。The oral composition of the present invention further comprises saccharin sodium, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, perillartin, thaumatin, asparatyl phenylalanine methyl ester,
p-methoxycinnamic aldehyde, sucrose, lactose,
Sweeteners such as fructose and sodium cyclamate (0-1
%, Preferably 0.01 to 0.5%), p-hydroxymethylbenzoic acid, p-hydroxyethylbenzoic acid, p-hydroxypropylbenzoic acid, p-hydroxybutylbenzoic acid, sodium benzoate, Preservatives such as lower fatty acid monoglyceride, wintergreen oil, spearmint oil, peppermint oil, sassafras oil, clove oil, eucalyptus oil and other flavors, gelatin, peptone, arginine hydrochloride, albumin, casein, brightener, silicone, pigment, Other components may be blended, for example, in the case of toothpaste, it may be produced by kneading the desired components described above with an appropriate amount of water.
【0027】また、他の口腔用組成物を製造する場合も
通常用いられている適宜な成分を使用し、常法に従って
製造することができる。Also, in the case of producing other oral compositions, it can be produced in accordance with a conventional method using appropriate components usually used.
【0028】なおまた、本発明においては、イプシロン
アミノカプロン酸、トラネキサム酸、デキストラナー
ゼ、アミラーゼ、プロテアーゼ、ムタナーゼ、リゾチー
ム、溶菌酵素、リテックエンザイム等の酵素、モノフル
オロリン酸ナトリウム、モノフルオロリン酸カリウムな
どのアルカリ金属モノフルオロホスフェート、フッ化ナ
トリウム、フッ化アンモニウム、フッ化第1錫等のフッ
化物、クロルヘキシジン塩類、ジヒドロコレステロー
ル、グリチルレチン塩類、グリチルレチン酸、クロロフ
ィル、カロペプタイド、ビタミン類、歯石防止剤、抗菌
剤、歯垢阻止剤、硝酸カリウムなどの公知の知覚過敏症
鈍麻剤等の有効成分を1種又は2種以上配合し得る。Furthermore, in the present invention, epsilon aminocaproic acid, tranexamic acid, dextranase, amylase, protease, mutanase, lysozyme, lytic enzyme, enzyme such as litec enzyme, sodium monofluorophosphate, potassium monofluorophosphate. Alkali metal monofluorophosphate, sodium fluoride, ammonium fluoride, fluorides such as stannous fluoride, chlorhexidine salts, dihydrocholesterol, glycyrrhetin salts, glycyrrhetinic acid, chlorophyll, caropeptide, vitamins, anticalculus agent, antibacterial One or two or more kinds of active ingredients such as known agents, antiplaque agents, and known sensitizers such as potassium nitrate may be blended.
【0029】本発明の口腔用組成物は、上述した成分を
適宜選択使用して調製し得るが、この場合組成物のpH
を5以上、より好ましくは5〜10、更に好ましくは6
〜8とすることが必要であり、pHが低い場合には知覚
過敏症を予防、治療する効果が発揮されない。なお、p
Hを調整する場合、pH調整剤として水酸化ナトリウ
ム、炭酸水素ナトリウム、炭酸ナトリウム等の水酸化ア
ルカリ、炭酸水素アルカリ、炭酸アルカリなどを添加す
ることができる。The oral composition of the present invention can be prepared by appropriately selecting and using the above-mentioned components. In this case, the pH of the composition is
Is 5 or more, more preferably 5 to 10, still more preferably 6
It is necessary to adjust the pH to -8, and if the pH is low, the effect of preventing and treating hypersensitivity cannot be exhibited. Note that p
When H is adjusted, alkali hydroxides such as sodium hydroxide, sodium hydrogen carbonate and sodium carbonate, alkali hydrogen carbonate and alkali carbonate can be added as pH adjusters.
【0030】[0030]
【発明の効果】本発明の口腔用組成物は、象牙細管狭窄
閉塞効果が非常に高く、象牙質知覚過敏症を有効に予
防、治療することができる。INDUSTRIAL APPLICABILITY The composition for oral cavity of the present invention has a very high effect of occluding dentinal tubule stenosis and can effectively prevent and treat dentine hyperesthesia.
【0031】[0031]
【実施例】以下、実験例及び実施例を示し、本発明を具
体的に説明するが、本発明は下記の実施例に制限される
ものではない。EXAMPLES The present invention will be specifically described below by showing experimental examples and examples, but the present invention is not limited to the following examples.
【0032】〔実験例〕パッシュレー(Pashle
y)の装置を用いて各種薬剤による象牙質の象牙細管の
狭窄及び閉塞の程度を評価した。ここで、知覚過敏症は
象牙細管内に存在する象牙細管液の移動により神経が刺
激されて生じるものであるが、パッシュレーの装置によ
ればこの象牙細管液の移動をin vitroで直接測
定できる。[Experimental Example] Pashley
The degree of stenosis and occlusion of dentin tubules of dentin by various agents was evaluated using the device of y). Here, the hyperesthesia is caused by the nerve being stimulated by the movement of the dentinal tubule fluid existing in the dentinal tubule, and the Pashley device can directly measure the movement of the dentinal tubule fluid in vitro.
【0033】具体的には、ヒトの歯牙から得られるデン
チンディスクを装置に組み込み、リンゲル液を加圧下で
送り込んだときのデンチンディスクの象牙細管を通過す
る局法リンゲル液の単位時間当りの液量を測定するもの
で、デンチンディスクを薬剤で処置する前後のリンゲル
液の単位時間当りの象牙細管通過液量から象牙細管の狭
窄又は閉塞の程度を評価するものである。Specifically, a dentin disc obtained from a human tooth is incorporated into an apparatus, and when the Ringer's solution is fed under pressure, the amount of the local Ringer's solution passing through the dentinal tubule of the dentin disc is measured per unit time. Therefore, the degree of stenosis or occlusion of dentinal tubules is evaluated from the amount of Ringer's liquid passing through the dentin tubules per unit time before and after treating the dentin disc with a drug.
【0034】なお、本実験において、薬剤としては表
1,2に示すものを表に示す通りの濃度で水に溶解し、
NaOHで所定pHに調整したものを使用し、これにデ
ンチンディスクを浸漬することにより処置を施した。こ
の場合、カルボン酸アルミニウムのうちアルミニウム分
が多いものは塩基性塩化アルミニウム〔Al(OH)2
Cl〕xとカルボン酸とをカルボン酸/Alが所定モル
比になるように使用し、カルボン酸分が多いものはカル
ボン酸アルミニウムにカルボン酸/Alが所定モル比に
なるようにカルボン酸を加えた。In this experiment, the drugs shown in Tables 1 and 2 were dissolved in water at the concentrations shown in the table,
Treatment was carried out by immersing a dentin disc in the one adjusted to a predetermined pH with NaOH. In this case, among the aluminum carboxylates having a high aluminum content, basic aluminum chloride [Al (OH) 2
Cl] x and carboxylic acid are used so that the carboxylic acid / Al has a predetermined molar ratio, and when the carboxylic acid content is large, carboxylic acid is added to aluminum carboxylate so that the carboxylic acid / Al has a predetermined molar ratio. It was
【0035】表1,2に各種薬剤の象牙細管狭窄閉塞効
果の結果を併記する。なお、象牙細管狭窄閉塞効果は下
記から求めた減少率により評価した。Tables 1 and 2 also show the results of the occluded dentinal stenosis obstruction effect of various drugs. The effect of occluding dentinal tubule stenosis was evaluated by the reduction rate obtained from the following.
【0036】[0036]
【数1】 [Equation 1]
【0037】[0037]
【表1】 [Table 1]
【0038】[0038]
【表2】 [Table 2]
【0039】表1,2の結果より、カルボン酸アルミニ
ウムに特定の水溶性リン酸化合物やシュウ酸化合物を併
用すると、象牙細管狭窄効果がより改善されることが認
められた。From the results in Tables 1 and 2, it was confirmed that the combined use of a specific water-soluble phosphoric acid compound or oxalic acid compound with aluminum carboxylate further improved the dentinal tubule stenosis effect.
【0040】以下、実施例を示す。 〔実施例1〕練歯磨 プロピレングリコール 5% カラギーナン 2 ゼラチン 0.3 ソルビット 15 水酸化アルミニウム 40 ラウリル硫酸ナトリウム 0.5 香料 0.5 サッカリンナトリウム 0.05 乳酸アルミニウム 1.0 硝酸カリ 5.0 リン酸二ナトリウム 0.6 モノフルオロリン酸ナトリウム 0.76水 残 計 100.0% pH=6.0(水酸化ナトリウムで調整)Examples will be shown below. [Example 1] Toothpaste Propylene glycol 5% Carrageenan 2 Gelatin 0.3 Sorbit 15 Aluminum hydroxide 40 Sodium lauryl sulfate 0.5 Perfume 0.5 Sodium saccharin 0.05 Aluminum lactate 1.0 Potassium nitrate 5.0 Diphosphate Sodium 0.6 Sodium monofluorophosphate 0.76 Water balance 100.0% pH = 6.0 (adjusted with sodium hydroxide)
【0041】 〔実施例2〕練歯磨 プロピレングリコール 3% キサンタンガム 2 グリセリン 20 アルミナ 10 ラウリル硫酸ナトリウム 2.0 香料 0.3 サッカリンナトリウム 0.05 クエン酸アルミニウム 3.5 ピロリン酸ナトリウム 1.0 クロルヘキシジングルコネート 0.01水 残 計 100.0% pH=5.5(水酸化ナトリウムで調整)[Example 2] Toothpaste Propylene glycol 3% Xanthan gum 2 Glycerin 20 Alumina 10 Sodium lauryl sulfate 2.0 Perfume 0.3 Saccharin sodium 0.05 Aluminum citrate 3.5 Sodium pyrophosphate 1.0 Chlorhexidine gluconate 0 0.01 Water Residual 100.0% pH = 5.5 (adjusted with sodium hydroxide)
【0042】 〔実施例3〕洗口剤 グリセリン 5.0% ソルビット 5.0 エタノール 10 サッカリンナトリウム 0.15 ラウリル硫酸ナトリウム 3.0 香料 0.5 色素 0.01 乳酸アルミニウム 2.0 リン酸二ナトリウム 0.4水 残 計 100.0% pH=7.0(水酸化カリウムで調整)[Example 3] Mouthwash Glycerin 5.0% Sorbit 5.0 Ethanol 10 Saccharin sodium 0.15 Sodium lauryl sulfate 3.0 Perfume 0.5 Dye 0.01 Aluminum lactate 2.0 Disodium phosphate 0 .4 Water balance 100.0% pH = 7.0 (adjusted with potassium hydroxide)
【0043】[0043]
【0044】〔実施例4〕洗口剤 pH=6.5(水酸化カリウムで調整)Example 4 Mouthwash pH = 6.5 (adjusted with potassium hydroxide)
【0045】〔実施例5〕口腔用バンド pH=7(水酸化ナトリウムで調整)Example 5 Oral band pH = 7 (adjusted with sodium hydroxide)
【0046】〔実施例6〕口腔用バンド pH=7.5(水酸化ナトリウムで調整) 上記実施例の口腔用バンドは各成分を水に溶解して10
0gの溶液とし、これを凍結乾燥して水分を可及的に除
去し、フィルム状に形成することにより作成した。Example 6 Oral band pH = 7.5 (adjusted with sodium hydroxide) The oral band of the above example was prepared by dissolving each component in water to give 10
A 0 g solution was prepared, which was freeze-dried to remove water as much as possible and formed into a film.
【0047】〔実施例7〕塗布用剤 pH=7.0(水酸化ナトリウムで調整)Example 7 Coating agent pH = 7.0 (adjusted with sodium hydroxide)
【0048】[0048]
Claims (12)
態で含有し、かつそのアルミニウム1モルに対するカル
ボン酸根のモル比が6以下である象牙細管狭窄閉塞有効
成分を配合していると共に、正リン酸、グリセロリン
酸、ピロリン酸、トリポリリン酸、ヘキサメタリン酸、
フィチン酸、エタン−1−ヒドロキシ−1,1−ジホス
ホン酸及びこれらのナトリウム塩、カリウム塩、アンモ
ニウム塩から選ばれる水溶性リン酸化合物を配合してな
り、かつpHが5以上であることを特徴とする象牙質知
覚過敏症用口腔用組成物。1. An dentinal tubule stenosis-occluding active ingredient containing aluminum and a carboxylic acid radical in a dissolved state and having a molar ratio of the carboxylic acid radical to 6 mol of aluminum is 6 or less, and orthophosphoric acid, Glycerophosphoric acid, pyrophosphoric acid, tripolyphosphoric acid, hexametaphosphoric acid,
Phytic acid, ethane-1-hydroxy-1,1-diphosphonic acid, and a water-soluble phosphoric acid compound selected from sodium salt, potassium salt, and ammonium salt thereof, and having a pH of 5 or more An oral composition for hypersensitivity of dentin.
根のモル比が0.3/n〜6/n(但し、nは一分子中
のカルボン酸根の数を示す)である特許請求の範囲第1
項記載の組成物。2. A molar ratio of carboxylic acid radicals to 1 mol of aluminum is 0.3 / n to 6 / n (where n represents the number of carboxylic acid radicals in one molecule).
The composition according to the item.
1項又は第2項記載の組成物。3. The composition according to claim 1 or 2 having a pH of 5-10.
である特許請求の範囲第1項乃至第3項いずれか1項記
載の組成物。4. The composition according to any one of claims 1 to 3, wherein the carboxylic acid radical is a hydroxycarboxylic acid radical.
ノカルボン酸根である特許請求の範囲第4項記載の組成
物。5. The composition according to claim 4, wherein the hydroxycarboxylic acid radical is a hydroxymonocarboxylic acid radical.
含有量が組成物全体の0.01〜10重量%である特許
請求の範囲第1項乃至第5項いずれか1項記載の組成
物。6. The composition according to claim 1, wherein the content of solubilized aluminum is 0.01 to 10% by weight based on the total weight of the composition.
酸根とを溶解状態で含有し、かつそのアルミニウム1モ
ルに対するカルボン酸根のモル比が6以下である象牙細
管狭窄閉塞有効成分を配合していると共に、シュウ酸化
合物を配合してなり、かつpHが5以上であることを特
徴とする象牙質知覚過敏症用口腔用組成物。7. An dentinal tubule stenosis-occluding active ingredient containing aluminum and a carboxylic acid radical other than oxalic acid in a dissolved state, and having a molar ratio of the carboxylic acid radical to 6 mol of aluminum is 6 or less, and An oral composition for hypersensitivity of dentin, which comprises an oxalic acid compound and has a pH of 5 or more.
根のモル比が0.3/n〜6/n(但し、nは一分子中
のカルボン酸根の数を示す)である特許請求の範囲第7
項記載の組成物。8. A molar ratio of carboxylic acid radicals to 1 mol of aluminum is 0.3 / n to 6 / n (where n represents the number of carboxylic acid radicals in one molecule).
The composition according to the item.
7項又は第8項記載の組成物。9. The composition according to claim 7, which has a pH of 5 to 10.
根である特許請求の範囲第7項乃至第9項いずれか1項
記載の組成物。10. The composition according to any one of claims 7 to 9, wherein the carboxylic acid radical is a hydroxycarboxylic acid radical.
モノカルボン酸根である特許請求の範囲第10項記載の
組成物。11. The composition according to claim 10, wherein the hydroxycarboxylic acid radical is a hydroxymonocarboxylic acid radical.
の含有量が組成物全体の0.01〜10重量%である特
許請求の範囲第7項乃至第11項いずれか1項記載の組
成物。12. The composition according to any one of claims 7 to 11, wherein the content of solubilized aluminum is 0.01 to 10% by weight based on the whole composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6075317A JP2550909B2 (en) | 1994-03-22 | 1994-03-22 | Oral composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6075317A JP2550909B2 (en) | 1994-03-22 | 1994-03-22 | Oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07165550A JPH07165550A (en) | 1995-06-27 |
JP2550909B2 true JP2550909B2 (en) | 1996-11-06 |
Family
ID=13572769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6075317A Expired - Lifetime JP2550909B2 (en) | 1994-03-22 | 1994-03-22 | Oral composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2550909B2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3877412B2 (en) * | 1996-12-16 | 2007-02-07 | アース製薬株式会社 | Liquid oral composition |
EP1413589A4 (en) * | 2001-07-13 | 2006-06-07 | Kao Corp | Polymers for oral use and compositions for oral use |
JP2006056846A (en) * | 2004-08-23 | 2006-03-02 | Sun Medical Co Ltd | Bleaching agent kit for tooth for suppressing hyperesthesia in bleaching |
JP2008184436A (en) * | 2007-01-30 | 2008-08-14 | Sun Medical Co Ltd | Hyperesthesia-suppressing dental abrasive material composition |
JP2016138047A (en) * | 2015-01-26 | 2016-08-04 | ライオン株式会社 | Dentifrice composition |
KR102076268B1 (en) * | 2015-04-17 | 2020-02-11 | 주식회사 엘지생활건강 | Oral composition |
JP2017141178A (en) * | 2016-02-09 | 2017-08-17 | ライオン株式会社 | Dentifrice composition |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA829272A (en) * | 1969-12-09 | Von Bismarck Gunther | Dental care and dental treatment agent |
-
1994
- 1994-03-22 JP JP6075317A patent/JP2550909B2/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
広島大学歯学雑誌,7〜2!(1975)P.60(152)−65(158) |
Also Published As
Publication number | Publication date |
---|---|
JPH07165550A (en) | 1995-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0742219B2 (en) | Oral composition | |
US11813342B2 (en) | Oral care compositions and methods of use | |
EP2934446B1 (en) | Oral care products comprising zinc oxide and trimethylglycine | |
RU2650609C2 (en) | Zinc phosphate containing compositions | |
EP3541346B1 (en) | Oral care compositions | |
JPH09503506A (en) | Oral composition | |
EP2934444B1 (en) | Oral care products comprising tetrabasic zinc chloride and trimethylglycine | |
JP2013541598A (en) | Dentifrice composition containing calcium silicate and basic amino acid | |
CZ156795A3 (en) | Mouth preparation containing agents against formation of microbial plaque, tartar, gingivitis and foetor ex ore | |
BR112018005749B1 (en) | Composition for oral care | |
JP2000154127A (en) | Composition for oral cavity | |
JPH01207227A (en) | Tartar preventing composition | |
JP2550909B2 (en) | Oral composition | |
JPH0629171B2 (en) | Oral composition | |
JPH06183940A (en) | Composition for oral cavity | |
JPH0629169B2 (en) | Oral composition | |
JPS60184007A (en) | Composition for oral cavity application | |
JPH0629170B2 (en) | Toothpaste composition | |
JPH03200718A (en) | Anti-calculous composition | |
JPH0796490B2 (en) | Toothpaste composition | |
EP0290186A2 (en) | Use of oral compositions comprising anti-calculus agents | |
JPH07165548A (en) | Composition for oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |